investor downgrad neutral tp
downgrad neutral downgrad teva neutral given
stock strong ytd perform see unattract
risk/reward ahead sept fda action date key pipelin product
fremanezumab lack meaning near mid-term catalyst
beyond event lower target price look manag
provid greater visibl futur growth driver come
becom construct stock
believ fremanezumab approv mid-sept expect launch
product immedi thereaft howev fda observ
made recent teva partner celltrion manufactur site still
resolv believ approv within next day increasingli
unlik addit believ expect fremanezumab commerci
potenti may high given market dynam cgrp space
possibl attract offer compani amgen/novarti
risk/reward less attract us limit clear near-term
driver move fremanezumab launch assumpt
lower market share assumpt modestli assum teva
third cgrp market expect team continu deliv
restructur teva believ gener expect see
underappreci driver upsid stori next month
base case target price base ebitda rel
valuat blue sky grey sky
ep estim chang
main risk view teva better anticip commerci
fremanezumab upsid poorer anticip oper
effici downsid
valuat metric
number share
price month
outperform neutral
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
teva israel-bas pharmaceut compani focus primarili
research develop commerci gener
specialti drug two oper segment gener medicin
specialti medicin
price sep rate outperform neutral target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat driven larg part effici
optim gener busi slower anticip
eros copaxon sale compani debt situat
grey sky valuat driven larg part bearish
assumpt around sale copaxon gener
busi us need renogoti debt
 close
cautiou optim mere caution
lack new inform celltrion leav fda
approv timelin teva fremanezumab unclear
cautiou longer cautious optimist teva fremanezumab
approv timelin mainli due lack news teva fremanezumab
manufactur celltrion inc resolv manufactur issu incheon south
korea manufactur site total eight observ made fda latest
sent celltrion inc figur concern process
procedur vial breakag untrain employe
figur celltrion inc form issu aug follow fda inspect jul
written procedur product process control repos glass vial breakag etc
employe engag process drug product lack train requir
routin check automat equip perform indic sensor use prior cap
procedur describ calibr certain devic defici written follow
absenc identif composit around certain bioreactor mention previou report
observ transfer harvest tank load tank distanc devic
lack procedur address downstream spill
failur document time temperatur sampl transfer freezer
although celltrion acquir drug product contract manufactur organ
cmo fix fill finish line issu lack materi updat celltrion
amelior issu fda sent call minor comment worri
aug note concern fremanezumab approv highlight celltrion
press releas regard juli fda re-inspect gave two differ
timelin resolv issu turn close fda warn letter mid-
august korean-languag version releas aug end august
english-languag version releas follow day
uncertainti compound current version press releas
updat day english version releas simpli say fda issu would
resolv soon celltrion group affili compani earn present last
week also provid addit inform despit investor hope
ceo celltrion healthcar also seat vice chairman celltrion
group includ celltrion inc actual manufactur fremanezumab would provid
updat
fact date pass news coupl
inconsist two report especi absenc warn letter
english version creat uncertainti whether celltrion resolv
issu fda teva still hit target approv septemb
fact follow teva manag regard celltrion appar delay
recent steadfastli reiter current timelin fda approv
fremanezumab septemb new inform given reiter
belief drug approv fda date compani
readi launch immedi thereaft
fremanezumab approv matter time make
differ
base data seen fremanezumab expect eventu
approv believ manufactur issu celltrion may push approv
month given intens competit cgrp space amgen/novarti
alreadi market expect obtain approv next month month
delay would make fremanezumab third market would meaning impact
outlook product view
believ weak teva stock past week may
relat investor becom cautiou on-tim fremanezumab approv
howev still see risk/reward skew downsid fda decis base
numer recent convers investor see potenti
relief ralli on-tim approv clean label includ quarterli dose
option potenti downsid approv come
even approv commerci challeng would
remain fremanezumab
strong aimovig volum uptak payer pushback yet kick
convers lead neurologist highlight strong interest cgrp
class doctor patient reflect strong prescript
volum amgen/novarti aimovig first three month market although
seen flatten volum declin nrx volum past
week unclear latest script trend suggest compani work
initi bolu patient eagerli anticip aimovig arriv may
see impact hurdl payer may implement recent trend
blip radar resolv move fall
howev also unclear strong volum may lead term actual sale
novarti provid aimovig free charg patient two month
sometim insur coverag drug final player
market littl freedom negoti payer assum
chang time competitor includ teva enter market like drive
net price per patient cgrp antibodi abl command
worrisom sign recent week
aimovig weekli trx nrx
disadvantag
brand new market could soon three major competitor teva boast one
could differenti
major potenti advantag
fremanezumab competit
teva aim label includ quarterli dose vs monthli dose
compani guid toward quarterli dose includ label
certainti fda agre especi concern
sinc patient receiv fremanezumab quarterli pivot trial still
receiv placebo inject interven month potenti cloud
interpret efficaci quarterli dose howev inclus quarterli dose
product label would power differenti factor would posit
teva compet success aimovig lilli galcanezumab time
teva product deliv pre-fil syring rather sophist
auto-injector like rival therefor disadvantag market
front patient uncomfort inject may prefer use
auto-injector need see needl
due volum requir full dose fremanezumab must given
three separ inject first day rather singl shot
constraint like also increas difficulti posit market
compet drug requir patient take singl inject month
possibl due high volum teva also saw much higher incid
inject site reaction drug arm placebo arm clinic
trial competitor continu clinic doctor
could move away recommend fremanezumab prefer option
figur percentag patient experienc inject reaction cgrp
us million unless otherwis state
analyst
compani data credit suiss estim bloomberg profession servic
strong progress new manag date
upsid like take time
highlight sever time year impress way
new teva manag team execut bold restructur plan date
manag clearli concis laid vision proceed meet
major goal far ahead schedul compani financi posit much
secur month ago
restructur on-going copaxon hold gener competit
better fear teva also put togeth solid perform first half
year beat expect teva stock also react
favor progress stock sinc kre schultz appoint ceo
sinc restructur plan first announc figur
charl martineau pm univers toronto figur index price perform teva pharma sinc
howev strong perform associ increas
compani full year financi guidanc wonder upsid come
come month also sens increas focu investor teva top
line growth outlook oppos upsid cost contain teva
comment expect grow top-line see
challeng even reason contribut austedo fremanezumab given
declin expect copaxon lose volum face greater
price pressur figur
charl martineau pm univers toronto figur gener version copaxon make inroad first month market
weekli nbrx share copaxon od copaxon glatopa od
note nbrx data week end aug also glatopa script
reflect real world usag data report restrict
figur also impact realiz price teva obtain per
figur credit suiss anticip copaxon sale hold better
consensu erod rapidli beyond
us million unless otherwis state
analyst
compani data credit suiss estim bloomberg profession servic
teva core busi remain gener aggress deflat seen
us gener drug price shown sign stabil still continu
figur us gener drug price trend show stabil deflat overal improv
cs sales-weight gener drug price monitor product sales-weight iqvia gener sales/ gener
yoy chg gener asp
iqvia cs healthcar technolog distribut team
brand pipelin product note nerv growth factor fasinumab
partner regeneron see promis especi light
us opioid epidem still sever year away make sort meaning
impact teva top bottom line overal expect teva return
sale growth expect growth fairli modest even
figur teva sale ep ebitda estim credit suiss vs
us million unless otherwis state
lack meaning catalyst also make us
comfort move neutral
us million unless otherwis state
fremanezumab anti-cgrp migrain
fremanezumab anti-cgrp migrain
us million unless otherwis state
sale
incom invest
incom incom tax
share loss associ compani net
net incom non-control interest
net gain loss attribut non-control interest
dividend prefer share
weight average share use calcul dilut ep
compani mention price
